Advertisement
Advertisement

ARMP

ARMP logo

Armata Pharmaceuticals, Inc. Common Stock

8.82
USD
Sponsored
-0.18
-2.00%
May 13, 16:00 UTC -4
Closed
exchange

Pre-Market

8.83

+0.01
+0.12%

Armata Pharmaceuticals, Inc. Common Stock Profile

About

Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.

Info & Links

CEO

Deborah Birx

Headquarters

5005 MCCONNELL AVE
LOS ANGELES, CA 90066, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.armatapharma.com

Auditor

Ernst & Young LLP

Share holders

68

Employees

61

Armata Pharmaceuticals, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

324.05M

Enterprise Value

572.29M

Enterprise Value/EBITDA(ttm)

-16.30

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

86.13

Price to Book(mrq)

--

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-1058.65%

Profit Margin(ttm)

-3959.75%

Return on Equity(ttm)

--

Return on Invested Capital(ttm)

-255.54%

Return on Assets(ttm)

-62.09%

Income Statement

Revenue(ttm)

4.90M

Revenue Per Share(ttm)

0.13

Gross Profit(ttm)

4.90M

EBITDA(ttm)3

-35.10M

Net Income Available to Common(ttm)

-173.80M

Diluted EPS(ttm)

-4.82

Share Statistics

Beta (5Y Monthly)

1.38

52-Week Change

521.13%

S&P 500 52-Week Change

26.33%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

36.63M

Dividend Yield

0.00%

Float4

5.68M

% Held by Insiders

84.50%

% Held by Institutions

3.57%

Balance Sheet

Total Cash(mrq)

8.69M

Total Cash Per Share(mrq)

0.24

Total Debt(mrq)

256.92M

Total Debt/Equity(mrq)

-117.53%

Current Ratio(mrq)

1.19%

Quick Ratio(mrq)

1.19%

Book Value Per Share(mrq)

-6.00

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.71

Free Cash Flow(ytd)

-26.30M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement